Emyria (ASX:EMD) announces ‘promising’ interim clinical results from analysis of its MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD) program, which commenced in October 2023.
- Interim analysis of the first eight patients completing Emyria’s MDMA-assisted therapy (MDMA-AT) program for Post-Traumatic Stress Disorder (PTSD) has demonstrated all patients achieved substantial improvement in PTSD symptoms, with a clinically and statistically significant average reduction of 33 points in PCL-5 scores.
- All patients reported substantial gains in quality of life, with a mean improvement of 22 points on the ReQoL scale, highlighting the broad impact of Emyria’s MDMA-AT program beyond symptom relief.
- Emyria continues to evolve its leading care programs by actively collecting and applying Real-World Data, setting the standard for PTSD care and reinforcing its global leadership in developing promising new mental health treatments.
- Emyria plans to leverage existing revenues to fund the expansion of its programs and is actively engaging with private hospitals and third-party payers to broaden access and secure reimbursement.
Michael Winlo, CEO of Emyria Limited, said: “These early Real-World results from our MDMA-Assisted Therapy program highlight the significant potential of this approach for PTSD care and provide an early indication of its effectiveness in real clinical settings beyond controlled trials. Emyria is uniquely positioned to lead the global development and refinement of this treatment as Australia is currently the only jurisdiction permitting these therapies under stringent oversight. We believe we have a substantial head start in gathering crucial Real-World Data and refining the approach to fully realise the potential of MDMA-AT thereby helping patients and also advancing the therapy’s ongoing improvement.”